Yuhan
Yuhan Corp is a South Korean pharmaceutical and chemical manufacturing company engaged in research, development, and commercialization of prescription drugs and healthcare goods. The company operates across primary business divisions including ethical prescription pharmaceuticals, over-the-counter consumer medicines, household chemicals, and active pharmaceutical ingredient manufacturing. Its product portfolio features targeted oncology therapies, cardiovascular treatments, metabolic disease medications, household cleaners, and specialized active ingredients supplied to global pharmaceutical partners. Principal revenue is derived from ethical drug sales through hospital channels, OTC medicine sales, household brand distributions, and international exports of custom active ingredients. Yuhan is one of South Korea's largest and oldest pharmaceutical corporations, recognized for its strategic licensing partnerships with global biopharmaceutical firms. Headquartered in Seoul, South Korea, the company's shares are publicly listed and traded on the Korea Exchange under the ticker 000100.
15 of the funds FundTelligence covers report a position in Yuhan.
- Legal name
- Yuhan Corp
- Sector
- Health Care
- Country
- South Korea
- Funds holding it
- 15
Funds holding Yuhan
- Danske Invest Global Emerging Markets Index Restricted — Danske Invest · 0.12 % (full portfolio disclosed, July 2026)
- Handelsbanken Emerging Markets Index — Handelsbanken · 0.05 % (full portfolio disclosed, September 2026)
- Mercer Passive Emerging Markets Equity Fund — Mercer · 0.04 % (full portfolio disclosed, December 2025)
- Lannebo Emerging Markets — Lannebo · 0.03 % (full portfolio disclosed, June 2026)
- Storebrand Emerging Markets — Storebrand · 0.03 % (full portfolio disclosed, October 2026)
- BlackRock iShares MSCI EM IMI Screened UCITS ETF — BlackRock · 0.03 % (full portfolio disclosed, October 2026)
- KLP AksjeFremvoksende Markeder Indeks — KLP · 0.02 % (full portfolio disclosed, June 2026)
- DNB Emerging Markets Index — DNB · 0.02 % (full portfolio disclosed, September 2026)
Showing the 8 largest of 15 funds holding it.